Neurosense Therapeutics Ltd expected to post a loss of 13 cents a share - Earnings Preview

Reuters

Jun 20, 2025

<a href="https://laohu8.com/S/NRSN">Neurosense Therapeutics Ltd</a> <nrsn.oq> expected to post a loss of 13 cents a share - Earnings Preview </nrsn.oq>

Neurosense Therapeutics Ltd NRSN.OQ NRSN.O is expected to report results on June 24 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Neurosense Therapeutics Ltd is for a loss of 13 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Neurosense Therapeutics Ltd is $10.75, above its last closing price of $2.45.

This summary was machine generated June 20 at 11:03 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2544297811"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544297811\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2544297811?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-20 19:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544297811","market":"us","top_or_hot":-1,"title":"Neurosense Therapeutics Ltd  expected to post a loss of 13 cents a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/NRSN\">Neurosense Therapeutics Ltd</a> <nrsn.oq> expected to post a loss of 13 cents a share - Earnings Preview </nrsn.oq></title></head><body><ul><li><p>Neurosense <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Ltd <span>NRSN.OQ</span> <span>NRSN.O</span> is expected to report results on June 24 (estimated) for the period ending March 31 2025</p></li><li></li><li><p>LSEG's mean analyst estimate for Neurosense Therapeutics Ltd is for a loss of 13 cents per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" 1 \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Neurosense Therapeutics Ltd is $10.75, above its last closing price of $2.45. </p></li></ul><p>This summary was machine generated June 20 at 11:03 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurosense Therapeutics Ltd  expected to post a loss of 13 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurosense Therapeutics Ltd  expected to post a loss of 13 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-20 19:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/NRSN\">Neurosense Therapeutics Ltd</a> <nrsn.oq> expected to post a loss of 13 cents a share - Earnings Preview </nrsn.oq></title></head><body><ul><li><p>Neurosense <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Ltd <span>NRSN.OQ</span> <span>NRSN.O</span> is expected to report results on June 24 (estimated) for the period ending March 31 2025</p></li><li></li><li><p>LSEG's mean analyst estimate for Neurosense Therapeutics Ltd is for a loss of 13 cents per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" 1 \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Neurosense Therapeutics Ltd is $10.75, above its last closing price of $2.45. </p></li></ul><p>This summary was machine generated June 20 at 11:03 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NRSN","symbol_name":"Neurosense Therapeutics Ltd","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nL8N3SN0L2:1","article_id":"2544297811","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544297811","pubTimestamp":1750417389,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Neurosense Therapeutics Ltd  expected to post a loss of13cents a share - Earnings Preview Neurosense Therapeutics Ltd NRSN.OQ NRSN.O is expected to report results on June 24 (estimated) for the period","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NRSN":"Neurosense Therapeutics Ltd"},"translate_title":"Neurosense Therapeutics Ltd预计每股亏损13美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRSN":0.9},"content_text":"Neurosense Therapeutics Ltd  expected to post a loss of 13 cents a share - Earnings Preview Neurosense Therapeutics Ltd NRSN.OQ NRSN.O is expected to report results on June 24 (estimated) for the period ending March 31 2025LSEG's mean analyst estimate for Neurosense Therapeutics Ltd is for a loss of 13 cents per share. The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" 1 \"hold\" and no \"sell\" or \"strong sell.\"  The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Neurosense Therapeutics Ltd is $10.75, above its last closing price of $2.45. This summary was machine generated June 20 at 11:03 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,preview","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}